Targeted Combo OK'd for Solid Tumors With BRAF V600E Mutation

(MedPage Today) -- The FDA has granted accelerated approval to the BRAF inhibitor dabrafenib (Tafinlar) combined with the MEK inhibitor trametinib (Mekinist) for the treatment of adults and children with unresectable or metastatic solid tumors...